This episode concerns an opinion from the Federal Circuit which addresses a patent dispute regarding genetically engineered host cells used in gene therapy. The court reversed a lower court's ruling that had invalidated the patent for allegedly claiming a natural phenomenon. The judges determined that the claimed cells are human-made inventions because they contain recombinant nucleic acid from different species, which does not exist in nature. By comparing the technology to landmark cases like Chakrabarty and Myriad, the court concluded that these modified cells possess "markedly different" characteristics from natural products. Consequently, the patent was deemed eligible for protection under federal law, and the case was sent back for further legal proceedings.
This podcast is for entertainment purposes only and does not create an attorney-client relationship. The AI-generated hosts are not attorneys and are not providing legal advice. The choice of a lawyer is an important decision and should not be based solely upon advertisements.
